Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma

By Skarbnik Alan P   Pro Barbara  

Expert Review of Hematology, Vol. 6, Iss. 1, 2013-02 ,pp. : 1-3

Informa Healthcare

Access to resources Recommend Favorite

Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma - A pilot study

By Xiros N.   Economopoulos T.   Valsami S.   Rontogianni D.   Fountzilas G.   Raptis S.  

Leukemia Research, Vol. 27, Iss. 12, 2003-12 ,pp. : 1097-1099

Elsevier

Access to resources Recommend Favorite

Phase II study of ifosfamide, etoposide, and oxaliplatin (IFETOx) chemotherapy for relapsed or refractory non-Hodgkin’s lymphoma

By Kim Seon-Kyeong   Song Moo-Kon   Chung Joo   Shin Ho-Jin  

International Journal of Hematology, Vol. 98, Iss. 5, 2013-11 ,pp. : 543-548

Springer Publishing Company

Access to resources Recommend Favorite

Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy

By Seshadri T.   Stakiw J.   Pintilie M.   Keating A.   Crump M.   Kuruvilla J.  

Hematology, Vol. 13, Iss. 5, 2008-10 ,pp. : 261-266

Maney Publishing

Access to resources Recommend Favorite

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

By Aydin Semra   Dührsen Ulrich   Nückel Holger  

Annals of Hematology, Vol. 86, Iss. 4, 2007-04 ,pp. : 271-276

Springer Publishing Company

Access to resources Recommend Favorite